J&J: Another recall, another earnings rise

Tuesday's Johnson & Johnson/McNeil recall of Tylenol 8-hour caplets is an unremarkable data point in the company's continuing quality-meltdown saga. It's on the small end of Tylenol recalls at just 128,000 bottles. And it's lacking in drama, following the congressional inquisition in which CEO Bill Weldon suffered a few body blows but nothing that knocked him down.

CNN Money was able to spice things up a bit by chronicling from 2003 the FDA inspection reports of the Fort Washington, PA plant involved in most of the recalls. Labeling issues were the problem in 2003, but a cornucopia of GMP violations mark inspection reports from 2006, 2008 and 2009. One source speculates that there was a change in QA management during that time.

Yet again, the company was able to please investors with a 2.2 percent earnings rise for the third quarter, which J&J announced virtually in tandem with the latest recall. Sales were down by less than 1 percent, notes the New York Times, barely a ding given the recall totality: infants' and children's liquid Tylenol, Motrin, Zyrtec, Benadryl and some adult Tylenol and related products. But the drop in sales garnered essentially a ho-hum from analysts.

The latest recall is not good news, of course, especially given its appearance during Weldon's campaign as fix-it man. That campaign encompasses the manufacturing quality issues that have plagued McNeil and that likely extend further into the J&J mega-structure, as well as the corresponding damage to its company and brand names.

- see the Times article
- here's the CNN report


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.